NIOX Group Plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSSPF research report →
Price Chart
About the company
Niox Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis and management of asthma. It offers NIOX VERO, a non-invasive point-of-care system that provides fractional exhaled nitric oxide (FeNO) measurements. The company was founded by Steven Harris and Charles Stuart Webb Swingland on May 19, 2006 and is headquartered in Oxford, the United Kingdom.
- CEO
- Jonathan Charles Emms
- IPO
- 2020
- Employees
- 97
- HQ
- Oxford, OX, GB
Get TickerSpark's AI analysis on CSSPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $378.32M
- P/E
- 40.48
- Fwd P/E
- 32.86
- PEG
- 1.20
- P/S
- 5.99
- P/B
- 4.29
- EV/EBITDA
- 18.26
- Div Yield
- 2.29%
- Gross Margin
- 60.42%
- Op Margin
- 21.89%
- Net Margin
- 14.74%
- ROE
- 10.01%
- ROIC
- 9.64%
Latest fiscal year · YoY change
- Revenue
- $48.69M+16.5%
- Gross Profit
- $29.60M-2.0%
- Op Income
- $10.70M
- Net Income
- $7.00M+89.2%
- EPS
- $0.02+92.0%
- OCF Growth
- -8.2%
- FCF Growth
- -3.7%
- 52W High
- $0.92
- 52W Low
- $0.75
- 50D MA
- $0.84
- 200D MA
- $0.85
- Beta
- -0.09
- RSI (14)
- 99
- Avg Volume
- 26
No earnings-call transcripts are available for CSSPF yet.
- Free Float
- 78.2%
- Shares Outstanding
- 420.87M
- Float Shares
- 329.25M
Our CSSPF coverage
Recent articles, reports, and earnings notes.
No research on CSSPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSSPF report →